HC Wainwright Issues Pessimistic Outlook for CBIO Earnings

Posted by Stanley Muller on May 6th, 2026

Crescent Biopharma, Inc. (NASDAQ:CBIO – Free Report) – Research analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for shares of Crescent Biopharma in a note issued to investors on Monday, May 4th. HC Wainwright analyst M. Kapoor now forecasts that the biopharmaceutical company will post earnings per share of ($0.79) for the quarter, down from their prior forecast of ($0.78). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Crescent Biopharma’s current full-year earnings is ($3.21) per share. HC Wainwright also issued estimates for Crescent Biopharma’s Q3 2026 earnings at ($0.80) EPS, FY2026 earnings at ($3.17) EPS, Q1 2027 earnings at ($0.99) EPS, Q2 2027 earnings at ($1.10) EPS, Q3 2027 earnings at ($1.20) EPS, Q4 2027 earnings at ($1.42) EPS and FY2027 earnings at ($4.71) EPS.

Crescent Biopharma (NASDAQ:CBIO – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.15. The firm had revenue of $1.04 million for the quarter, compared to analyst estimates of $0.36 million.

A number of other research firms have also recently weighed in on CBIO. Guggenheim initiated coverage on Crescent Biopharma in a report on Wednesday, January 21st. They set a “buy” rating and a $35.00 price target on the stock. Stifel Nicolaus set a $29.00 target price on Crescent Biopharma in a research report on Thursday, February 26th. Wall Street Zen raised Crescent Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Piper Sandler started coverage on Crescent Biopharma in a research report on Wednesday, January 28th. They set an “overweight” rating and a $35.00 price target for the company. Finally, Weiss Ratings cut Crescent Biopharma from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday, April 29th. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Crescent Biopharma currently has a consensus rating of “Buy” and an average target price of $28.00.

Read Our Latest Stock Analysis on Crescent Biopharma

Crescent Biopharma Trading Up 0.9%

Shares of NASDAQ CBIO opened at $18.08 on Wednesday. Crescent Biopharma has a 12-month low of $8.72 and a 12-month high of $27.97. The company has a market cap of $498.28 million, a price-to-earnings ratio of -1.66 and a beta of 1.21. The stock’s 50 day simple moving average is $16.27 and its 200 day simple moving average is $13.63.

Institutional Trading of Crescent Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of the business. Jefferies Financial Group Inc. increased its stake in Crescent Biopharma by 279.1% in the 3rd quarter. Jefferies Financial Group Inc. now owns 102,714 shares of the biopharmaceutical company’s stock valued at $1,221,000 after buying an additional 75,618 shares during the period. Soleus Capital Management L.P. acquired a new stake in shares of Crescent Biopharma during the 2nd quarter valued at $6,456,000. Heights Capital Management Inc. purchased a new position in shares of Crescent Biopharma during the 4th quarter valued at $3,131,000. Alyeska Investment Group L.P. purchased a new position in shares of Crescent Biopharma during the 4th quarter valued at $3,109,000. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Crescent Biopharma in the fourth quarter worth $1,325,000. Institutional investors and hedge funds own 75.19% of the company’s stock.

Crescent Biopharma Company Profile

(Get Free Report)

Crescent Biopharma, Inc (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth.

The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis.